ARTICLE | Clinical News

Cotara: Interim Phase II data

October 25, 2010 7:00 AM UTC

Interim data from 14 evaluable patients in an ongoing, open-label, U.S. and Indian Phase II trial showed that a single, 25-hour intratumoral infusion of Cotara at first relapse resulted in a median OS of 86 weeks at a follow-up duration ranging from 4-107 weeks. Peregrine said expected survival for patients with GBM is typically 24 weeks from the time of disease recurrence. Mean PFS and OS were 55 and 60 weeks, respectively. The trial is enrolling up to 40 patients. Data were presented at the Neurological Surgeons meeting in San Francisco. Peregrine previously reported data from 10 evaluable patients showing that Cotara led to a median recurrence-free survival of 33 weeks and a median OS of 41 weeks (see BioCentury, Sept. 7, 2009). ...